Safety and Efficacy of Brolucizumab in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis

REFERENCES

• Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14. doi:10.1016/j.diabres.2009.10.007.
   PubMed Web of Science ®Google Scholar
• Kobrin Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–183. doi:10.1080/09286580701396720.
   PubMed Web of Science ®Google Scholar
• Zhang X, Saaddine JB, Chou C-F, et al. Prevalence of Diabetic Retinopathy in the United States, 2005-2008. JAMA. 2010;304(6):649–656. doi:10.1001/jama.2010.1111.
   PubMed Web of Science ®Google Scholar
• Bandello F. Diabetic Macular Edema. Dev Ophthalmol. 2017;58:102–138.
   PubMedGoogle Scholar
• Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012;60(5):428–431. doi:10.4103/0301-4738.100542.
   PubMed Web of Science ®Google Scholar
• Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14(4):179–183. doi:10.1080/09286580701396720.
   PubMed Web of Science ®Google Scholar
• Jain A, Varshney N, Smith C. The evolving treatment options for diabetic macular edema. Int J Inflam. 2013;2013:1–10. doi:10.1155/2013/689276.
   Google Scholar
• Lanzetta P, Loewenstein A. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1259–1273. doi:10.1007/s00417-017-3647-4.
   PubMed Web of Science ®Google Scholar
• Yorston D. Anti-VEGF drugs in the prevention of blindness. Community Eye Health. 2014;27:44–46.
   PubMedGoogle Scholar
• Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, et al. Guidelines for the management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222. doi:10.1159/000458539.
   PubMed Web of Science ®Google Scholar
• Li E, Donati S, Lindsley KB, et al. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2020;5(5):Cd012208. doi:10.1002/14651858.CD012208.pub2.
   PubMed Web of Science ®Google Scholar
• Mansour SE, Browning DJ, Wong K, et al. The evolving treatment of diabetic retinopathy. Clin Ophthalmol. 2020;14:653–678. doi:10.2147/OPTH.S236637
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Maguire MG, et al. Early response to anti–vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. American Journal Of Ophthalmology. 2018;195:93–100. doi:10.1016/j.ajo.2018.07.030
   PubMed Web of Science ®Google Scholar
• Sorour OA, Levine ES, Baumal CR, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023;68(2):147–174. doi:10.1016/j.survophthal.2022.11.008.
   PubMed Web of Science ®Google Scholar
• Busch C, Zur D, Fraser-Bell S, et al. Shall we stay, or shall we switch? Continued anti-VEGF therapy versus early switch to dexamethasone implant in refractory diabetic macular edema. Acta Diabetol. 2018;55(8):789–796. doi:10.1007/s00592-018-1151-x.
   PubMed Web of Science ®Google Scholar
• Sivaprasad S, Crosby-Nwaobi R, Heng LZ, et al. Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT report 5). Br J Ophthalmol. 2013;97(9):1177–1180. doi:10.1136/bjophthalmol-2013-303168.
   PubMed Web of Science ®Google Scholar
• Laiginhas R, Silva MI, Rosas V, et al. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):83–89. doi:10.1007/s00417-017-3836-1.
   PubMed Web of Science ®Google Scholar
• Bahrami B, Hong T, Schlub TE, et al. AFLIBERCEPT for PERSISTENT DIABETIC MACULAR EDEMA: forty-eight-week outcomes. Retina. 2019;39(1):61–68. doi:10.1097/IAE.0000000000002253.
   PubMed Web of Science ®Google Scholar
• Bruè C, Pazzaglia A, Mariotti C, et al. Aflibercept as primary treatment for myopic choroidal neovascularisation: a retrospective study. Eye (Lond). 2016;30(1):139–145. doi:10.1038/eye.2015.199.
   PubMed Web of Science ®Google Scholar
• Rahman EZ, Singer MA. Brolucizumab as treatment of wet age-related maculopathy. Drugs Today (Barc). 2020;56(11):699–704. doi:10.1358/dot.2020.56.11.3199812.
   PubMed Web of Science ®Google Scholar
• Tadayoni R, Sararols L, Weissgerber G, et al. Brolucizumab: a newly developed anti-VEGF molecule for the Treatment of Neovascular Age-Related Macular Degeneration. Ophthalmologica. 2021;244(2):93–101. doi:10.1159/000513048.
   PubMed Web of Science ®Google Scholar
• Dugel PU, Singh RP, Koh A, et al. HAWK and HARRIER: ninety-six-week outcomes from the phase 3 trials of Brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2021;128(1):89–99. doi:10.1016/j.ophtha.2020.06.028.
   PubMed Web of Science ®Google Scholar
• Brown DM, Emanuelli A, Bandello F, et al. KESTREL and KITE: 52-week results from two phase III pivotal trials of Brolucizumab for Diabetic Macular Edema. Am J Ophthalmol. 2022;238:157–172. doi:10.1016/j.ajo.2022.01.004
   PubMed Web of Science ®Google Scholar
• Witkin AJ, Hahn P, Murray TG, et al. Occlusive retinal vasculitis following Intravitreal Brolucizumab. J Vitreoretin Dis. 2020;4(4):269–279. doi:10.1177/2474126420930863.
   PubMedGoogle Scholar
• Muka T, Glisic M, Milic J, et al. A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol. 2020;35(1):49–60. doi:10.1007/s10654-019-00576-5.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
   PubMed Web of Science ®Google Scholar
• Study Quality Assessment Tools | NHLBI, NIH | https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.
   Google Scholar
• Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046–1050. doi:10.1097/IAE.0b013e3181d87e04.
   PubMed Web of Science ®Google Scholar
• Busch M, Pfeil JM, Dähmcke M, et al. Anti-drug antibodies to brolucizumab and ranibizumab in serum and vitreous of patients with ocular disease. Acta Ophthalmol. 2022;100(8):903–910. doi:10.1111/aos.15124.
   PubMed Web of Science ®Google Scholar
• Chakraborty D, Mondal S, Parachuri N, Kumar N, Sharma A. Brolucizumab—early experience with early extended interval regime in chronic centre involved diabetic macular oedema. Eye (Lond). 2022;36(2):358–360. doi:10.1038/s41433-021-01816-3.
   PubMed Web of Science ®Google Scholar
• Murray JE, Gold AS, Latiff A, et al. Brolucizumab: evaluation of compassionate use of a complex anti-VEGF therapy. Clin Ophthalmol. 2021;15:4731–4738. doi:10.2147/OPTH.S339393
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Sheth JU, Campa C. Contralateral effect following intravitreal brolucizumab injection in diabetic macular Edema. Case Rep Ophthalmol Med. 2022;2022:1–4. doi:10.1155/2022/3755249.
   Web of Science ®Google Scholar
• Mahapatra SK, Das A. Initial experience in off-label use of brolucizumab in diabetic macular ededama and retinal vein occlusion. Current Indian Eye Res J Ophthalmic Res Group. 2021;54(49):51.
   Google Scholar
• Hirano T, Toriyama Y, Takahashi Y, et al. Retinal arterial occlusive vasculitis after multiple intravitreal brolucizumab injections for diabetic macular edema. Am J Ophthalmol Case Rep. 2023;29:101788. doi:10.1016/j.ajoc.2022.101788
   PubMedGoogle Scholar
• Chakraborty D, Sheth JU, Boral S, et al. Off-label intravitreal brolucizumab for recalcitrant diabetic macular edema: a real-world case series. Am J Ophthalmol Case Rep. 2021;24:101197. doi:10.1016/j.ajoc.2021.101197
   PubMedGoogle Scholar
• Hänsli C, Schild C, Pfister I, Garweg JG. Brolucizumab in pretreated neovascular age-related macular degeneration: case series, systematic review, and meta-Analysis. Life. 2023;13(3):814. doi:10.3390/life13030814.
   PubMedGoogle Scholar
• Table 25 , all ocular serious adverse events in the study eye (Safety Analysis Set). 2015.
   Google Scholar
• Hikichi T. Sub-Tenon’s capsule triamcinolone acetonide injection to prevent brolucizumab-associated intraocular inflammation. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2529–2535. doi:10.1007/s00417-022-05611-y.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang W, Gao Y, et al. The efficacy and safety of Current treatments in diabetic macular Edema: a systematic review and network meta-analysis. PLoS One. 2016;11(7):e0159553. doi:10.1371/journal.pone.0159553.
   PubMed Web of Science ®Google Scholar
• Xie X, Lian C, Zhang Z, et al. Aflibercept for long-term treatment of diabetic macular edema and proliferative diabetic retinopathy: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1144422. doi:10.3389/fendo.2023.1144422
   PubMed Web of Science ®Google Scholar
• Baumal CR, Bodaghi B, Singer M, et al. Expert opinion on management of intraocular inflammation, retinal vasculitis, and vascular occlusion after brolucizumab treatment. Ophthalmol Retina. 2021;5(6):519–527. doi:10.1016/j.oret.2020.09.020.
   PubMedGoogle Scholar
• Baumal CR, Spaide RF, Vajzovic L, et al. Retinal vasculitis and intraocular inflammation after Intravitreal Injection of Brolucizumab. Ophthalmology. 2020;127(10):1345–1359. doi:10.1016/j.ophtha.2020.04.017.
   PubMed Web of Science ®Google Scholar
• Monés J, Srivastava SK, Jaffe GJ, et al. Risk of inflammation, retinal vasculitis, and retinal occlusion–related events with Brolucizumab. Ophthalmology. 2021;128(7):1050–1059. doi:10.1016/j.ophtha.2020.11.011.
   PubMed Web of Science ®Google Scholar
• Holz FG, Iida T, Maruko I, Sadda SR. A CONSENSUS on RISK MITIGATION for BROLUCIZUMAB in NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: patient selection, evaluation, and treatment. Retina. 2022;42(9):1629–1637. doi:10.1097/IAE.0000000000003556.
   PubMed Web of Science ®Google Scholar
• Ogura Y, Jaffe GJ, Cheung CMG, et al. Efficacy and safety of brolucizumab versus aflibercept in eyes with polypoidal choroidal vasculopathy in Japanese participants of HAWK. Br J Ophthalmol. 2022;106(7):994–999. doi:10.1136/bjophthalmol-2021-319090.
   PubMed Web of Science ®Google Scholar
• Garweg JG. A randomized, double-masked, multicenter, phase III study assessing the efficacy and Safety of Brolucizumab versus aflibercept in patients with visual impairment due to Diabetic Macular Edema (KITE). Klin Monbl Augenheilkd. 2020;237(4):450–453. doi:10.1055/a-1101-9126.
   PubMed Web of Science ®Google Scholar
• Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: preclinical assessment and mitigation. Clin Immunol. 2013;149(3):534–555. doi:10.1016/j.clim.2013.09.006.
   PubMed Web of Science ®Google Scholar
• Hirano T, Kumazaki A, Tomihara R, Ito S, Hoshiyama K, Murata T. Evaluating initial responses to brolucizumab in patients undergoing conventional anti-VEGF therapy for diabetic macular edema: a retrospective, single-center, observational study. Sci Rep. 2023;13(1):10901. doi:10.1038/s41598-023-37726-5.
   PubMed Web of Science ®Google Scholar
• Pan WW, Lin F, Fort PE. The innate immune system in diabetic retinopathy. Prog Retinal Eye Res. 2021;84:100940. doi:10.1016/j.preteyeres.2021.100940.
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Matsumoto H, Barakat MR, et al. Retinal vasculitis or vascular occlusion after brolucizumab for neovascular age-related macular degeneration: a systematic review of real-world evidence. Retina. 2023;43(7):1051–1063. doi:10.1097/IAE.0000000000003769.
   PubMed Web of Science ®Google Scholar